The interaction of chalcones with tubulin

Anti-Cancer Drug Design

Volumn 15, Issue 2, 2000, Pages 135-141

  Lawrence, Nicholas J ^a   McGown, Alan T ^b   Ducki, Sylvie ^a,b   Hadfield, John A ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Antimitotic; Chalcones; Cytotoxic; Microtubules; Oestrogen receptor; Tubulin

Indexed keywords

CHALCONE; CYTOTOXIC AGENT; ESTROGEN RECEPTOR; TUBULIN;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROTUBULE ASSEMBLY; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHALCONE; DRUG DESIGN; HUMANS; INDICATORS AND REAGENTS; K562 CELLS; MICROTUBULES; MOLECULAR STRUCTURE; PROPIOPHENONES; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TUBULIN; VERO CELLS;

EID: 0034087870     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Anto R.J., Sukumaran K., Kuttan G., Rao M.N.A., Subbaraju V., Kuttan R. (1995) Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Letters, 97, 33.
2. De Vincenzo R., Scambia G., Benedetti Panici P., Ranelletti F.O., Bonanno G., Ercoli A., Delle Monache F., Ferrari F., Piantelli M., Mancuso S. (1995) Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth structure-activity relationships. Anti-Cancer Drug Design, 10, 481.
3. Ducki S., Hadfield J.A., Lawrence N.J., Zhang X., McGown A.T. (1995) Isolation of paeonol from Arisaema erubescens. Planta Medica, 62, 586.
4. Ducki S., Hadfield J.A., Lawrence N.J., Liu C.-Y., Zhang X., McGown A.T. (1996a) Isolation of (E)-1-(4-hydroxyphenyl)-1-buten-3-one from Scutellaria barbata. Planta Medica, 62, 185.
5. Ducki S., Hadfield J.A., Lawrence N.J., Zhang X., McGown A.T. (1996b) Isolation of aurantiamide acetate from Arisaema erubescens. Planta Medica, 62, 277.
6. Ducki S., Hadfield J.A., Hepworth L.A., Lawrence N.J., Liu C.-Y., McGown A.T. (1997) Synthesis and cell growth inhibitory properties of substituted (E)-1-phenylbut-1-enones. Bioorganic, Medicinal Chemistry Letters, 7, 3091.
7. Ducki S., Forrest R., Hadfield J.A., Kendall A., Lawrence N.J., McGown A.T., Rennison D. (1998) Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorganic, Medicinal Chemistry Letters, 8, 1051.
8. Edmondson J.M., Armstrong L.S., Martinez A.O. (1988) A rapid and simple MTT-based assay for determining drug sensitivity in monolayer cultures. Journal of Tissue Culture Methods, 22, 2293.
9. Edwards M.L., Stemerick D.M., Sunkara P.S. (1990) Chalcones: a new class of antimitotic agent. Journal of Medicinal Chemistry, 33, 1948.
10. Fuller G.M., Brinkley B.R., Boughter J.M. (1975) Immunofluorescence of mitotic spindles by using monospecific antibodies against bovine brain tubulin. Science, 287, 948.
11. Gutsche C.D., Jason E.F., Coffey R.S., Johnson H.E. (1958) Experiments in the colchicine field. V. The thermal and photochemical decomposition of various 2-(β-phenylethyl)-phenyldiazomethanes and 2-(γ-phenylpropyl)-phenyldiazomethanes. Journal of the American Chemical Society, 80, 5756.
12. Herencia F., Ferrandiz M.L., Ubeda A., Dominguez J.N., Charris J.E., Lobo G.M., Alcaraz M.J. (1998) Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorganic, Medicinal Chemistry Letters, 8, 1169.
13. Hsieh H.K., Lee T.H., Wang J.P., Wang J.J., Lin C.N. (1998) Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharmaceutical Research, 15, 39.
14. Iwata S., Nishino T., Inoue H., Nagata N., Satomi Y., Nishino H., Shibata S. (1997) Antitumorigenic activities of chalcones - (II). Photo-isomerization of chalcones and the correlation with their biological activities. Biological, Pharmaceutical Bulletin, 20, 1266.
15. Jordan A.M., Hadfield J.A., Lawrence N.J., McGown A.T. (1998) Tubulin as a target for anticancer drugs. Medicinal Research Reviews, 18, 259.
16. Kamei H., Koide T., Hashimoto Y., Kojima T., Hasegawa M. (1997) Tumor cell growth suppression by chalcone (1,3-diphenyl-2-propen-1-one) Cancer Biotherapy and Radiopharmaceuticals, 12, 51.
17. Li R., Kenyon G.L., Cohen F.E., Chen X., Gong B., Dominguez J.N., Davidson E., Kurzban G., Miller R.E., Nuzum E.O., Rosenthal P., McKerrow J.H. (1995) In vitro antimalarial activity of chalcones and their derivatives. Journal of Medicinal Chemistry, 38, 5031.
18. McGown A.T., Fox B.W. (1989) Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A-4 and amphethinile. Anti-Cancer Drug Design, 3, 249.
19. McGown A.T., Poppit D.G., Swindell R., Fox B.W. (1984) The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate resisitant (L1210/R7/A) line, studied by flow cytometric and chromosome number analysis. Cancer Chemotherapy and Pharmacology, 23, 47.
20. McGown A.T., Jayson G., Pettit G.R., Haran M.S., Ward T.H., Crowther D. (1998) Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. British Journal of Cancer, 77, 216.
21. Na G.C., Timasheff S.N. (1986) Interaction of vinblastine with calf brain tubulin - multiple equilibria. Biochemistry, 25, 6214.
22. Rao M.N.A., Naidoo L., Ramanan P.N. (1991) Anti-inflammatory activity of phenyl styryl ketones. Pharmazie, 46, 542.
23. Sato M., Tsuchiya H., Akagiri M., Fujiwara S., Fujii T., Takagi N., Matsuura N., Iinuma M. (1994) Growth inhibitory properties of chalcones to Candida. Letters in Applied Microbiology, 18, 53.
24. Sato M., Tsuchiya H., Akagiri M., Takagi N., Iinuma M. (1997) Growth inhibition of oral bacteria related to denture stomatitis by anti-candidal chalcones. Australian Dental Journal, 42, 343.
25. Scambia G., Ranelletti F.O., Benedetti Panici P., Piantelli M., Bonanno G., De Vincenzo R., Ferrandina G., Runi C., Larocca L.M., Mancuso S. (1990) Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. British Journal of Cancer, 62, 942.
26. Searcey M., McClean S., Madden B., McGown A.T., Wakelin L.P.G. (1998) Synthesis, DNA-cleaving properties, and cytotoxicity of intercalating chelidamic acid derivatives. Anti-Cancer Drug Design, 13, 837.
27. Star A.E., Mabry T.J. (1971) Flavanoid frond exudates from the Jamaican ferns Pityrogramma tatrarea and P. calomelanos. Phytochemistry, 10, 2817.
28. Turigoe T., Arisawa M., Itoh S., Fujiu M., Maruyama H.B. (1983) Anti-mutagenic chalcones: antagonizing the mutagenicity of benzo(a)pyrene on Salmonella typhimurium. Biochemical and Biophysical Research Communications, 122, 833.
29. Woods J.A., Hadfield J.A., Pettit G.R., Fox B.W., McGown A.T. (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. British Journal of Cancer, 72, 705.